Age-related macular degeneration (AMD) is the leading cause of vision loss among older adults, characterized by gradual loss of central vision due to damage to the macula. Symptoms often include blurriness and difficulty seeing in low light. The most advanced form, geographic atrophy (GA), involves cell death in the retina, leading to progressively worsening vision. Until 2023, no therapies existed to manage GA, but recent FDA-approved injectable drugs provide new avenues for slowing disease progression. Researchers are also exploring gene and cell therapies as potential future interventions to treat AMD effectively.
The retina is home to the photoreceptor cells - rods and cones - that detect light and allow for vision.
Recent approvals of injectable drugs to slow the progression of geographic atrophy mark a significant advance in AMD treatment.
Collection
[
|
...
]